TBPH · As filed with the SEC
Theravance Biopharma balance sheet, by fiscal year
The statement as Theravance Biopharma presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED BALANCE SHEETS · USD
| USD | FY2025 Dec 31, 2025 | FY2024 Dec 31, 2024 | FY2023 Dec 31, 2023 | FY2022 Dec 31, 2022 | FY2021 Dec 31, 2021 | FY2020 Dec 31, 2020 | FY2019 Dec 31, 2019 | FY2018 Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Current assets: | ||||||||
| Cash and cash equivalents | 167,806,000 | 37,797,000 | 39,545,000 | 298,172,000 | 89,959,000 | 81,467,000 | 58,064,000 | 378,021,000 |
| Short-term marketable securities | 147,551,000 | 50,553,000 | 62,881,000 | 29,312,000 | 83,506,000 | 211,474,000 | 222,767,000 | 127,255,000 |
| Accounts receivable, net of allowances of $0 at December 31, 2019 and 2018, respectively | — | — | — | — | — | — | — | 620,000 |
| Receivables from collaborative arrangements | 45,539,000 | 18,440,000 | 17,474,000 | 16,785,000 | 14,065,000 | 15,868,000 | 11,996,000 | 10,053,000 |
| Prepaid taxes | — | — | — | — | — | — | — | 310,000 |
| Receivables from licensing arrangements | — | — | — | — | — | — | 10,000,000 | — |
| Amounts due from TRC, LLC | — | — | — | — | 43,534,000 | 53,799,000 | 28,574,000 | — |
| Receivables from milestones and royalty assets | 50,000,000 | 50,000,000 | — | — | — | — | — | — |
| Prepaid clinical and development services | — | 73,000 | 2,038,000 | 1,513,000 | 10,245,000 | 20,374,000 | — | — |
| Other prepaid and current assets | 7,564,000 | 4,204,000 | 11,603,000 | 7,682,000 | 8,561,000 | 10,359,000 | 7,087,000 | 16,564,000 |
| Inventories | — | — | — | — | — | — | — | 0 |
| Total current assets | 418,460,000 | 161,067,000 | 133,541,000 | 353,464,000 | 249,870,000 | 393,341,000 | 338,488,000 | 532,823,000 |
| Long-term marketable securities | 11,128,000 | — | — | — | — | — | 4,985,000 | 11,869,000 |
| Property and equipment, net | 5,895,000 | 7,418,000 | 9,068,000 | 11,875,000 | 13,657,000 | 16,422,000 | 12,644,000 | 13,176,000 |
| Operating lease assets | 24,371,000 | 28,354,000 | 36,287,000 | 40,126,000 | 39,690,000 | 43,260,000 | 46,604,000 | — |
| Equity in net assets of TRC, LLC | — | — | — | — | 67,537,000 | 12,750,000 | — | — |
| Tax receivable | — | — | — | — | — | — | 3,682,000 | — |
| Restricted cash | — | — | — | — | — | — | — | 833,000 |
| Future contingent milestone and royalty assets | — | 144,200,000 | 194,200,000 | 194,200,000 | — | — | — | — |
| Restricted cash | 836,000 | 836,000 | 836,000 | 836,000 | 837,000 | 833,000 | 833,000 | — |
| Other assets | 24,880,000 | 12,286,000 | 8,067,000 | 6,899,000 | 3,228,000 | 2,451,000 | 1,590,000 | 1,534,000 |
| Total assets | 485,570,000 | 354,161,000 | 381,999,000 | 607,400,000 | 374,819,000 | 469,057,000 | 408,826,000 | 560,235,000 |
| Current liabilities: | ||||||||
| Accounts payable | 2,568,000 | 2,242,000 | 1,524,000 | 1,554,000 | 3,098,000 | 6,775,000 | 4,758,000 | 9,028,000 |
| Accrued personnel-related expenses | 12,592,000 | 7,019,000 | 6,443,000 | 10,314,000 | 12,796,000 | 35,238,000 | 28,180,000 | 23,803,000 |
| Accrued clinical and development expenses | 3,373,000 | 1,058,000 | 2,246,000 | 4,932,000 | 17,010,000 | 28,799,000 | 17,587,000 | 11,876,000 |
| Accrued general and administrative expenses | 2,052,000 | 2,987,000 | 2,900,000 | 4,020,000 | 2,898,000 | 6,048,000 | — | — |
| Operating lease liabilities | 10,945,000 | 10,712,000 | 3,923,000 | 6,753,000 | 503,000 | 9,867,000 | 7,762,000 | — |
| Deferred revenue | — | — | — | 24,000 | 98,000 | 11,523,000 | 31,575,000 | 43,402,000 |
| Income tax payable | 5,287,000 | 5,853,000 | — | — | — | — | — | — |
| Other accrued liabilities | 1,485,000 | 2,214,000 | 1,241,000 | 1,118,000 | 1,304,000 | 2,013,000 | 6,331,000 | 10,445,000 |
| Accrued interest payable | — | — | — | — | 3,940,000 | 3,974,000 | 5,659,000 | — |
| Non-recourse notes due 2033, net | — | — | — | — | — | — | 9,851,000 | — |
| Current portion of non-recourse notes due 2035, net | — | — | — | — | 16,940,000 | 19,334,000 | — | — |
| Tenant improvement payable to sublessee | — | — | 6,490,000 | — | — | — | — | — |
| Total current liabilities | 38,302,000 | 32,085,000 | 24,767,000 | 28,715,000 | 58,587,000 | 123,571,000 | 111,703,000 | 98,554,000 |
| Long-term operating lease liabilities | 31,758,000 | 39,108,000 | 45,236,000 | 45,407,000 | 52,681,000 | 47,220,000 | 47,725,000 | — |
| Future royalty payment contingency | 32,795,000 | 30,334,000 | 27,788,000 | 25,438,000 | — | — | — | — |
| Long-term deferred revenue | — | — | — | 192,000 | 310,000 | 348,000 | 6,761,000 | 26,179,000 |
| Unrecognized tax benefits | — | 75,199,000 | 65,294,000 | 64,191,000 | — | — | — | — |
| Unrecognized tax benefits | 85,679,000 | — | — | — | — | — | — | — |
| Other long-term liabilities | 313,000 | 1,890,000 | 5,919,000 | 1,657,000 | 2,420,000 | 1,833,000 | 21,287,000 | 24,762,000 |
| Convertible senior notes due 2023, net | — | — | — | — | 228,035,000 | 226,963,000 | 225,890,000 | 224,818,000 |
| Non-recourse notes due 2035, net | — | — | — | — | 371,359,000 | 372,873,000 | — | — |
| Non-recourse notes due 2033, net | — | — | — | — | — | — | 219,300,000 | 229,535,000 |
| Deferred rent | — | — | — | — | — | — | — | 7,976,000 |
| Shareholders' Equity | ||||||||
| Ordinary shares, $0.00001 par value per share: 200,000 shares authorized; 51,069 and 49,471 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 1,000 | — | — | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 |
| Additional paid-in capital | 1,156,288,000 | 1,141,060,000 | 1,122,164,000 | 1,295,725,000 | 1,387,469,000 | 1,222,818,000 | 1,024,614,000 | 960,721,000 |
| Accumulated other comprehensive income | 61,000 | 7,000 | (65,000) | (15,000) | — | 47,000 | 145,000 | (166,000) |
| Accumulated deficit | (859,627,000) | (965,522,000) | (909,104,000) | (853,911,000) | (1,726,043,000) | (1,526,617,000) | (1,248,600,000) | (1,012,145,000) |
| Total shareholders' equity | 296,723,000 | 175,545,000 | 212,995,000 | 441,800,000 | (338,573,000) | (303,751,000) | (223,840,000) | (51,589,000) |
| Total liabilities and shareholders' equity | 485,570,000 | 354,161,000 | 381,999,000 | 607,400,000 | 374,819,000 | 469,057,000 | 408,826,000 | 560,235,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.